Cost Effectiveness of Palivizumab for Respiratory Syncytial Virus Prophylaxis in High-Risk Children
- 1 January 2007
- journal article
- Published by Springer Science and Business Media LLC in PharmacoEconomics
- Vol. 25 (1), 55-71
- https://doi.org/10.2165/00019053-200725010-00006
Abstract
No abstract availableKeywords
This publication has 27 references indexed in Scilit:
- National Institute for Clinical Excellence and its value judgmentsBMJ, 2004
- Does NICE have a cost‐effectiveness threshold and what other factors influence its decisions? A binary choice analysisHealth Economics, 2004
- Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart diseaseThe Journal of Pediatrics, 2003
- Respiratory syncytial virus infectionThe Lancet, 1999
- Respiratory syncytial virus immune globulin for prophylaxis against respiratory syncytial virus disease in infants and children with congenital heart diseaseThe Journal of Pediatrics, 1998
- Palivizumab, a Humanized Respiratory Syncytial Virus Monoclonal Antibody, Reduces Hospitalization From Respiratory Syncytial Virus Infection in High-risk InfantsPEDIATRICS, 1998
- The Selection of Data Sources For Use in Modelling StudiesPharmacoEconomics, 1998
- Ribavirin and bronchiolitis: variation in use in the UKArchives of Disease in Childhood, 1997
- Pediatric Investigators Collaborative Network on Infections in Canada (PICNIC) prospective study of risk factors and outcomes in patients hospitalized with respiratory syncytial viral lower respiratory tract infectionThe Journal of Pediatrics, 1995
- Respiratory Syncytial Viral Infection in Infants with Congenital Heart DiseaseThe New England Journal of Medicine, 1982